CC
CRDF icon

Caxton Corporation’s Cardiff Oncology CRDF Stock Holding History

Caxton Corporation’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,287
Closed -$41.7K – 13
2025
Q1 		$41.7K Hold
13,287
– – 0.82% 9
2024
Q4 		$57.7K Buy
+13,287
New +$41.5K 0.35% 11
2022
Q1 		– Sell
-2,522,083
Closed -$15.2M – 38
2021
Q4 		$15.2M Hold
2,522,083
– – 12.39% 2
2021
Q3 		$16.8M Buy
2,522,083
+178,750
+8% +$1.12M 13.61% 1
2021
Q2 		$15.6M Buy
2,343,333
+228,493
+11% +$1.94M 10.68% 3
2021
Q1 		$19.6M Hold
2,114,840
– – 12.72% 3
2020
Q4 		$38M Buy
2,114,840
+269,676
+15% +$4.74M 23.72% 1
2020
Q3 		$26.2M Buy
1,845,164
+250,000
+16% +$1.65M 24.69% 1
2020
Q2 		$7.99M Buy
+1,595,164
New +$3.26M 8.44% 3

Other funds holding CRDF

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Caxton Corporation's CRDF Position: Q2 2025 in Review

Caxton Corporation sold out of Cardiff Oncology (CRDF) in Q2 2025, closing a stake of 13,287 shares — an estimated $41.7K sold.

Caxton Corporation first reported a position in CRDF in Q2 2020 and held it in 9 quarters. The position peaked at $38M in Q4 2020. 114 funds tracked by Wall St. Rank hold CRDF as of Q2 2025.

  • Caxton Corporation reported no remaining Cardiff Oncology position as of Q2 2025 after selling out during the quarter.
  • Caxton Corporation sold 13,287 Cardiff Oncology shares in Q2 2025, an estimated $41.7K.
  • Caxton Corporation first reported a position in Cardiff Oncology in Q2 2020 and held it in 9 quarters.
  • Caxton Corporation's Cardiff Oncology position peaked at $38M in Q4 2020.
  • 114 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2025.

Based on Caxton Corporation's 13F filing for Q2 2025, filed 14 Aug 2025.